Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences, Inc. (RNA) Interest & Investment Income (2020 - 2025)

Avidity Biosciences' Interest & Investment Income history spans 6 years, with the latest figure at $17.9 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 3.66% year-over-year to $17.9 million; the TTM value through Dec 2025 reached $63.3 million, up 11.2%, while the annual FY2025 figure was $63.3 million, 11.2% up from the prior year.
  • Interest & Investment Income reached $17.9 million in Q4 2025 per RNA's latest filing, up from $14.7 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $18.5 million in Q4 2024 to a low of $16000.0 in Q1 2021.
  • Average Interest & Investment Income over 5 years is $7.5 million, with a median of $6.0 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: crashed 88.81% in 2021, then surged 7794.12% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $55000.0 in 2021, then skyrocketed by 4940.0% to $2.8 million in 2022, then soared by 131.06% to $6.4 million in 2023, then skyrocketed by 189.34% to $18.5 million in 2024, then fell by 3.66% to $17.9 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Interest & Investment Income are $17.9 million (Q4 2025), $14.7 million (Q3 2025), and $14.5 million (Q2 2025).